Figure 3From: In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapyEffect of the number of shRNA, efficacy, marking and level of inhibition on cellular compartments. Cells within each compartment are expressed as a percentage of all cells and monitored over 5000 days. Scenarios include: A) 6 shRNAs (S1), B) 4 shRNAs (S2), C) 2 shRNAs (S3), D) 60n % efficacy (S4), E) 1% marking (S5) and F) Class II inhibition only (S11). Assumptions for each scenario are indicated where - x = number of shRNA, - e = efficacy, - HSC+ = hematopoietic stem cells transduced to contain the gene therapeutic and - f = fitness.Back to article page